echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Development of innovative hair loss therapy El Jian reached research and development cooperation

    Development of innovative hair loss therapy El Jian reached research and development cooperation

    • Last Update: 2020-06-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Nucleic acid drugs play a therapeutic role by targeting potentially pathogenic genesHowever, reducing toxicity and effective delivery of drugs are the biggest technical challenges in the development of nucleic acid drugsExicure's proprietary SNA technology, which densely sequences nucleic acids with potential efficacy, is densely oriented on nanoparticles, either targeting a gene or arranging different nucleic acid sequences to achieve bispecificity or even three specificitySNA can be achieved through four mechanisms of action: antonym nucleic acid, siRNA, TLR9 activation, and splicing conversionIf not subject to additional chemical modification, linear nucleic acids are systematically delivered, usually collected in the liver and quickly cleanedUnlike linear oligonucleotides, SNA enters cells through the ubiquitous scavenger receptors, which can be delivered throughout the body or locally to target tissues, including the central nervous system, eyes, skin, gastrointestinal tract, lungs, liver, etcSNA has a high cellular intake capacity, without the need for in vitro encapsulation or compound preparation, and has a strong extra-hepatic delivery capacity, as well as extended half-life, indicating increased intracellular stability3-dimensional structure of the SNA (Photo: Source: Reference: 2)the main direction of this collaboration is androgen hair loss, which is one of the most common hair loss disordersIn the United States, the disease affects about 50 million men and 30 million womenIt is estimated that the annual cost of treatment exceeds $3.5 billion, most of which are ineffectiveunder the terms of the agreement, ElJian will pay Exicure a $25 million advance paymentAt that time, if ElJian exercises its options, it will be responsible for clinical and market-oriented developmentFor each new treatment, Exicure will receive a cost of up to $97.5 million in research and development and regulatory milestones, as well as a market-based milestone payment of up to $265 millionDr David Giljohann, ceo ofExicure, said: "Exicure is pleased to combine our knowledge of nucleic acid therapy with El Jian's deep expertise in medical aesthetics to develop and promote innovative treatments for hair lossThis collaboration is an exciting opportunity to advance Exicure's SNA technology in important new therapeutic areas " References: Exicure and Allergan Enter Into Collaboration, Option and License Agreement to Discover and Develop SNA-based Treatments for Hair Loss Disorders Retrieved Nov 14, 2019, from http://investors.exicuretx.com/news-releases/news-release-details/exicure-and-allergan-enter-collaboration-option-and-license 2 s Exicure is developing acid nucles son on olly siosssaic Sna ic Acid (SNA) technology Retrieved Nov 14, 2019, from https://exicuretxcom.ipage.com/assets/PDFs/Exicure_Corporate_Presentation.pdf
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.